Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Gain Therapeutics Q3 2026 Results: Net Loss of $3.16M, Loss Narrows

Gain Therapeutics reported a net loss of $13.4 million for the nine months ended September 30, 2026, with cash and cash equivalents decreasing to $11.7 million from $20.8 million at year-end 2025. The company highlighted its ongoing reliance on additional financing to support its Magellan™ platform and clinical development programs.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax-3.1-4.7
Net income-3.2-5.3
EPS (diluted, $ a share)$-0.07$-0.15

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: GANX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Gain Therapeutics, Inc.: key numbers

Share price
$0.9402Close, Nov 16
Market cap
$41.9M
Shares outstanding
44.53MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Gain Therapeutics, Inc.

All →
4:07 PM ET 8-K
Financial Results

Gain Therapeutics Financial Results

Gain Therapeutics reported financial results for the third quarter of 2026, highlighted by long-term Phase 1b data for rexaceract showing no motor symptom progression in Parkinson’s disease patients over 12 months. The company plans to initiate a Phase 2 clinical trial for rexaceract in Q1 2027 and select an initial therapeutic indication for its second candidate, GT-04686, by the end of 2026.

Term
Q3 2026

“The third quarter marked an important period of progress for Gain, highlighted by the presentation of long-term open-label data from the Phase 1b trial of rexaceract in Parkinson’s disease (PD). After 12 months of dosing with rexaceract, participants enrolled in the study showed no progression of Parkinson’s disease motor symptoms.”

Gene Mack, President and CEO of Gain Therapeutics

“As we approach the start of the Phase 2 clinical trial of rexaceract, which we expect to initiate during Q1 2027 after confirming updates to our trial design during Q4 2026, we plan to select an initial therapeutic indication to advance GT-04686 into the clinic.”

Gene Mack, President and CEO of Gain Therapeutics
5:01 PM ET 8-K
Executive Compensation

Gain Therapeutics Executive Compensation

Gain Therapeutics appointed Jeanette Weidner as Vice President, Finance, and principal financial and accounting officer, effective October 28, 2026. Her compensation package includes an annual base salary of $275,000, a target annual cash bonus of 35%, and an option to purchase 130,000 shares of common stock vesting over four years.

9:16 AM ET 8-K
Clinical Trial Data

Gain Therapeutics Clinical Trial Data

Gain Therapeutics presented 12-month open-label extension data from its Phase 1b study of rexaceract, showing stabilization of MDS-UPDRS motor scores in Parkinson’s disease patients. The data suggests disease-modifying potential as patients showed no clinically meaningful progression of motor symptoms over the one-year period. The company plans to submit a Phase 2 protocol to the FDA and initiate a Phase 2 trial in Q1 2027.

Term
12 months
4:31 PM ET 8-K
Leadership Change

Gain Therapeutics Leadership Change

Gianluca Fuggetta resigned as Senior Vice President of Finance, principal financial officer, and principal accounting officer effective September 30, 2026. Gene Mack, the company's current President and CEO, has been appointed to serve as interim Chief Financial Officer effective October 1, 2026, while the company searches for a permanent replacement.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.